Êîíòàêòû/Ïðîåçä  Äîñòàâêà è Îïëàòà Ïîìîùü/Âîçâðàò
Èñòîðèÿ
  +7(495) 980-12-10
  ïí-ïò: 10-18 ñá,âñ: 11-18
  shop@logobook.ru
Ðîññèéñêàÿ ëèòåðàòóðà
   
    Ïîèñê êíèã                    Ïîèñê ïî ñïèñêó ISBN Ðàñøèðåííûé ïîèñê    
Íàéòè
  Çàðóáåæíûå èçäàòåëüñòâà Ðîññèéñêèå èçäàòåëüñòâà  
Àâòîðû | Êàòàëîã êíèã | Èçäàòåëüñòâà | Íîâèíêè | Ó÷åáíàÿ ëèòåðàòóðà | Àêöèè | Õèòû | |
 
Âîéòè
Ðåãèñòðàöèÿ  Çàáûëè?

Cryosols / Permafrost-Affected Soils, Kimble John M.
Kimble John M. Cryosols / Permafrost-Affected Soils 9783540207511

Âàðèàíòû ïðèîáðåòåíèÿ
Öåíà: 36570.00ð.
Êîë-âî:
Íàëè÷èå: Ïîñòàâêà ïîä çàêàç.  Åñòü â íàëè÷èè íà ñêëàäå ïîñòàâùèêà.
Ñêëàä Àìåðèêà: Åñòü  
Ïðè îôîðìëåíèè çàêàçà äî: 2025-07-28
Îðèåíòèðîâî÷íàÿ äàòà ïîñòàâêè: Àâãóñò-íà÷àëî Ñåíòÿáðÿ
Ïðè óñëîâèè íàëè÷èÿ êíèãè ó ïîñòàâùèêà.
Äîáàâèòü â êîðçèíó
â Ìîè æåëàíèÿ

Àâòîð: Kimble John M.
Íàçâàíèå:  Cryosols / Permafrost-Affected Soils
ISBN: 9783540207511
Èçäàòåëüñòâî: Springer
Êëàññèôèêàöèÿ:
Íàóêè î æèçíè (ìåäèêî-áèîëîãè÷åñêèå): îáùèå âîïðîñû

Ãåîëîãèÿ è ëèòîñôåðà

Ïî÷âîâåäåíèå, ñåäèìåíòîëîãèÿ

Ãåîãðàôèÿ

Çàãðÿçíåíèå îêðóæàþùåé ñðåäû è äðóãèå óãðîçû

Ïðèðîäíûå áåäñòâèÿ

ISBN-10: 3540207511
Îáëîæêà/Ôîðìàò: Hardback
Ñòðàíèöû: 726
Âåñ: 1.22 êã.
Äàòà èçäàíèÿ: 2004
ßçûê: English
Èëëþñòðàöèè: 115 black & white illustrations, 25 black & white
Ðàçìåð: 23.55 x 16.28 x 4.52
×èòàòåëüñêàÿ àóäèòîðèÿ: Professional & vocational
Ïîäçàãîëîâîê: Permafrost-affected soils
Ññûëêà íà Èçäàòåëüñòâî: Link
Ðåéòèíã:
Ïîñòàâëÿåòñÿ èç: Ãåðìàíèè
Îïèñàíèå: Monitoring Committees: Why and How–David L. DeMets, Curt D. Furberg, Lawrence M. Friedman .-Lessons Learned–David L. DeMets .- FDA Perspective–Susan S. Ellenberg and Jay P. Siegel.- Introduction–Lawrence M. Friedman .- Assessing Possible Late Treatment Effects Early- The Diabetic Retinopathy Study Experience–Fred Ederer .- Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial- Early Experiences in Formal Monitoring Methods–Lawrence M. Friedman, David L. DeMets and Robert Hardy .- Data Monitoring for the Aspirin Component of the Physicians Health Study- Importance of Secondary Outcomes–David L. DeMets and Charles H. Hennekens .- Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial- Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance–Robert G. Hart, Lesly A. Pearce, Ruth McBride and Richard A. Kronmal .- Early Termination of the Diabetes Control and Complications Trial – Methodologic Issues–John M Lachin, Patricia Cleary, Oscar Crofford, Saul Genuth, David Nathan, Charles Clark, Frederick Ferris, and Carolyn Sieberg for the DCCT Research Group .- Data Monitoring in the AIDS Clinical Trials Group Study #981- Conflicting Interim Results–Dianne Finkelstein .- Challenges in Monitoring the Breast Cancer Prevention Trial–Carol K. Redmond,Joseph P. Costantino andTheodore Colton .- Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure- Potentially High Risk Treatment in High Risk Patients–Jan Feyzi, Desmond Julian, John Wikstrand and Hans Wedel .- Stopping the Randomized Aldactone Evaluation Study Early for Efficacy–Janet Wittes, Jean-Pierre Boissel, Curt Furberg, Desmond Julian, Henri Kulbertus and Stuart Pocock .- Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials- Avoiding Important Information Loss–Janice Pogue, David Sackett, George Wyse and Salim Yusuf .- Data Monitoring in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program–Stuart Pocock, Duolao Wang,Lars Wilhelmsen andCharles Hennekens .- Intro–Curt D. Furberg .- Breaking New Ground - Data Monitoring in the Coronary Drug Project–Paul L. Canner .- Data Monitoring in the Cardiac Arrhythmia Suppression Trial – The Need to Be Prepared Early–David L. DeMets and Lawrence M. Friedman .- Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation Trial- Dealing with an Agonizing Trend–Susan Anderson, Robert Cody, Milton Packer andRichard Schwarz .- Stopping the Carotene and Retinol Efficacy Trial - The Viewpoint of the Safety and Endpoint Monitoring Committee–Anthony B. Miller, Julie Buring and O. Dale Williams .- Monitoring a Clinical Trial with Waiver of Informed Consent: Diaspirin Cross-Linked Hemoglobin for Emergency Treatment of Post - Traumatic Shock–Roger L. Lewis and Norman Fost .- Challenges in Monitoring the Heart and Estrogen/progestin Replacement Study–Stephen B. Hulley,Deborah Grady, Eric Vittinghoff and O. Dale Williams .- Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial- Early Termination of the Doxazosin Arm–Barry R. Davis and Jeffrey A. Cutler .- Data Monitoring in the Moxonidone Congestive Heart Failure Trial–Stuart Pocock, Lars Wilhelmsen, Kenneth Dickstein, Gary Francis and Janet Wittes .- Data Monitoring of a Placebo-controlled Trial of Daclizumab in Acute Graft-versus-Host Disease–David Zahrich, Stephanie J. Lee and David Harrington .- Introduction–David L. DeMets .- Clinical Trials of Herpes Simplex Encephalitis: The Role of the Data Monitoring Committee–Richard J. Whitley .- The Nocturnal Oxygen Therapy Trial Data Monitoring Experience – Problem with Reporting Lags–David L. DeMets, George W. Williams andByron W. Brown, Jr. .- The Cooperative North Scandinavian Enalapril Survival Study II Trial–Steven Snapinn and Curt D. Furberg .- Lessons from Warfarin Trials in Atrial Fibrillation- Missing the Window of Opportunity–Charles H. Tegeler and Curt D. Furberg .- Data Monitoring in the Clinical Programs for Clinical Research in AIDS: The Toxoplasmic Encephalitis Study–James D. Neaton, Deborah N. Wentworth and Mark A. Jacobson .- Data Monitoring in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study: When Reasonable People Disagree–Janice Pogue and Salim Yusuf .- Data Monitoring in the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study:Hazards of Changing Primary Outcomes–Desmond Julian.- Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer–Stephen L. George and Mark R. Green .- Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial–Janet Wittes, Eric Holmgren, Heidi Christ-Schmidt and Alex Bajamonde726
Äîïîëíèòåëüíîå îïèñàíèå: Ôîðìàò: 235x155
Êðóã ÷èòàòåëåé: Scientists and graduate students in the fields of soil science and conservation, geoecology, hydrology and agriculture
Êëþ÷åâûå ñëîâà: Soil Science
Biogeosciences
Soil Conservation
Geoecology
Geography
ßçûê: eng
Îãëàâëåíèå: The History of Research of Polar Soil.- The Geography of Cryosols.- Properties and Processes of Cryosols.- Ecological Processes of Cryosols.- Classification of Cryosols.- Management and Use of Cryosols.  




Integrated management of salt affected soils in agriculture

Àâòîð: Nesreen Houssein Ahmen Ab
Íàçâàíèå: Integrated management of salt affected soils in agriculture
ISBN: 012804165X ISBN-13(EAN): 9780128041659
Èçäàòåëüñòâî: Elsevier Science
Ðåéòèíã:
Öåíà: 4714.00 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå:

Integrated Management of Salt Affected Soils in Agriculture is a concise guide to evaluating and addressing soil issues related to saline content. Methods focused, the book combines agricultural and soil-based insights to efficiently remediate salt-affected soil.

Environmental stress conditions such as salinity have a devastating impact on plant growth and yield, causing considerable loss to agricultural production worldwide. Soil salinity control prevents soil degradation by salinization and reclaim already saline soils. This book will help develop the proper management procedures, to solve problems of crop production on salt-affected soils.

ÎÎÎ "Ëîãîñôåðà " Òåë:+7(495) 980-12-10 www.logobook.ru
Åñòü âîïðîñ?
Ïîëèòèêà êîíôèäåíöèàëüíîñòè
Ïîìîùü
Äèñòðèáüþòîðû èçäàòåëüñòâà "Ëîãîñôåðà"
Î êîìïàíèè
Ïðåäñòàâèòåëüñòâî â Êàçàõñòàíå
 
Medpublishing.ru 
   Â Êîíòàêòå     Â Êîíòàêòå Ìåä  Ìîáèëüíàÿ âåðñèÿ